About Trial

A Potential New Option for Targeted Treatment of Pancreatic Cancer is on the Horizon

TIGeR-PaC is Enrolling Patients

The Phase III TIGeR-PaC clinical trial is currently enrolling unresectable locally advanced pancreatic cancer patients. TIGeR-PaC is a randomized study of Trans-Arterial Micro-Perfusion (TAMP) versus systemic chemotherapy. The goal of the trial is to prove extended median survival and improved quality of life through targeted delivery of therapy.

Unlike other treatments that are given intravenously with TAMP the chemotherapy is delivered intra-arterially directly into the pancreas. There is evidence that suggests delivering chemotherapy via an artery close to the tumor is an effective method for shrinking or stabilizing certain types of cancer.*

TIGeR-PaC is a randomized study currently enrolling unresectable Locally Advanced Pancreatic Cancer patients. In Phase I/II studies chemotherapy delivered directly via the TAMP procedure was associated with more than half the patients living over two years.* TIGeR-PaC, which currently has approximately 30 active clinical sites, is ultimately expected to involve 200 participants in the US and Europe.

*Agah, Ramtin, Rosemurgy, Alexander. Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma, Journal of Pancreatic Cancer; Vol. 3, issue 1.

Increasing Published Research Demonstrates RenovoCath’s Utility for Targeted Treatment of Pancreatic Cancer with Improved Safety and Survival